STOCK TITAN

Guardant Health (GH) director Meghan Joyce gains 4,203 shares from RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Guardant Health, Inc. director Meghan V. Joyce reported the vesting and settlement of a restricted stock unit award into common stock. On June 17, 2026, coinciding with the company’s 2026 Annual Meeting of Stockholders, 4,203 restricted stock units converted into 4,203 shares of common stock at no exercise price. Following this compensation-related transaction, Joyce directly holds 15,386 shares of Guardant Health common stock, and no open-market purchases or sales were reported in this filing.

Positive

  • None.

Negative

  • None.
Insider Joyce Meghan V.
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 4,203 $0.00 --
Exercise Common Stock 4,203 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 15,386 shares (Direct, null)
Footnotes (1)
  1. The restricted stock unit award vested in full on the date of the 2026 Annual Meeting of Stockholders which was held on June 17, 2026. Not applicable for Restricted Stock Units.
RSUs converted 4,203 shares Restricted Stock Units converted to common stock on June 17, 2026
Exercise price $0.00 per share Conversion price for restricted stock units into common stock
Shares after transaction 15,386 shares Direct common stock holdings following RSU conversion
Transactions acquiring shares 2 transactions Both classified as acquire via derivative exercise/conversion
Derivative exercises 4,203 shares ExerciseShares in transaction summary for derivative exercises
Restricted Stock Units financial
"The restricted stock unit award vested in full on the date of the 2026 Annual Meeting of Stockholders"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Annual Meeting of Stockholders financial
"the 2026 Annual Meeting of Stockholders which was held on June 17, 2026"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Joyce Meghan V.

(Last)(First)(Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/17/2026M4,203A$015,386D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$006/17/2026M4,203 (1) (2)Common Stock4,203$00D
Explanation of Responses:
1. The restricted stock unit award vested in full on the date of the 2026 Annual Meeting of Stockholders which was held on June 17, 2026.
2. Not applicable for Restricted Stock Units.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Meghan Verena Joyce06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Guardant Health (GH) director Meghan V. Joyce report?

Meghan V. Joyce reported the vesting and conversion of 4,203 restricted stock units into common stock. This was a compensation-related event, not an open-market trade, and reflects stock-based awards settling into actual Guardant Health shares.

How many Guardant Health (GH) shares did Meghan V. Joyce acquire in this Form 4?

Meghan V. Joyce acquired 4,203 shares of Guardant Health common stock through the exercise of restricted stock units. These RSUs converted at an exercise price of $0.00 per share when they vested, increasing her direct common stock holdings.

What are Meghan V. Joyce’s Guardant Health (GH) holdings after this transaction?

After the RSU conversion, Meghan V. Joyce directly holds 15,386 shares of Guardant Health common stock. This figure comes from the post-transaction ownership reported in the Form 4 and reflects only her direct holdings disclosed in this filing.

Was the Guardant Health (GH) insider transaction a market buy or sale?

The transaction was neither a market buy nor a sale; it was a derivative exercise. Restricted stock units vested and converted into 4,203 common shares at $0.00 per share, representing stock-based compensation rather than trading on the open market.

When did the reported Guardant Health (GH) restricted stock units vest?

The restricted stock unit award vested in full on June 17, 2026. This date coincided with Guardant Health’s 2026 Annual Meeting of Stockholders, triggering the automatic conversion of 4,203 RSUs into an equal number of common shares.